Exploiting the pleiotropic actions of GLP-1 for the management of type 2 diabetes mellitus and its complications

Diabetes Research and Clinical Practice

Volumn 78, Issue 3 SUPPL., 2007, Pages

  Giorgino, Francesco ^a   Natalicchio, Annalisa ^a   Leonardini, Anna ^a   Laviola, Luigi ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Cells; Brain; GLP 1; Heart; Insulin secretion; Lung

Indexed keywords

ALBUGON; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1;

ARTICLE; CARDIOVASCULAR SYSTEM; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECT; DRUG MECHANISM; FOOD INTAKE; GLUCAGON RELEASE; GLUCOSE HOMEOSTASIS; GLUCOSE TRANSPORT; HEART INFARCTION; HUMAN; INSULIN RELEASE; NERVOUS SYSTEM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PERIPHERAL NEUROPATHY; PLEIOTROPY; RESPIRATORY SYSTEM; STOMACH EMPTYING;

EID: 36549069100     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2007.09.022     Document Type: Article

References (57)

1. Perfetti R., and Merkel P. Glucagon-like peptide-1: a major regulator of pancreatic beta-cell function. Eur. J. Endocrinol. 143 (2000) 717-725
2. Buteau J., Roduit R., Susini S., and Prentki M. Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells. Diabetologia 42 (1999) 856-864
3. Wang X., Zhou J., Doyle M.E., and Egan J.M. Glucagon-like peptide-1 causes pancreatic duodenal homeobox-1 protein translocation from the cytoplasm to the nucleus of pancreatic beta-cells by a cyclic adenosine monophosphate/protein kinase A-dependent mechanism. Endocrinology 142 (2001) 1820-1827
4. Buteau J., Foisy S., Rhodes C.J., Carpenter L., Biden T.J., and Prentki M. Protein kinase C zeta activation mediates glucagon-like peptide-1-induced pancreatic β-cell proliferation. Diabetes 50 (2001) 2237-2243
5. MacDonald P.E., El-Kholy W., Riedel M.J., Salapatek A.M., Light P.E., and Wheeler M.B. The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion. Diabetes 51 (2002) S434-S442
6. Farilla L., Bulotta A., Hirshberg B., Li Calzi S., Khoury N., Noushmehr H., et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 144 (2003) 5149-5158
7. Farilla L., Hui H., Bertolotto C., Kang E., Bulotta A., Di Mario U., et al. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 143 (2002) 4397-4408
8. Li Y., Hansotia T., Yusta B., Ris F., Halban P.A., and Drucker D.J. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J. Biol. Chem. 278 (2003) 471-478
9. Holst J.J. Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1. Diabetes Metab. Res. Rev. 18 (2002) 430-441
10. Creutzfeldt W.O., Kleine N., Willms B., Orskov C., Holst J.J., and Nauck M.A. Glucagonostatic actions and reduction of fasting hyperglycaemia by exogenous glucagon-like peptide-1 (7-36) amide in type I diabetic patients. Diabetes Care 19 (1996) 580-586
11. Dunning B.E., Foley J.E., and Ahren B. Alpha cell function in health and disease: influence of glucagon-like peptide-1. Diabetologia 48 (2005) 1700-1713
12. De Leon D.D., Crutchlow M.F., Ham J.Y., and Stoffers D.A. Role of glucagon-like peptide-1 in the pathogenesis and treatment of diabetes mellitus. Int. J. Biochem. Cell Biol. 38 (2006) 845-859
13. Wang Y., Kole H.K., Montrose-Rafizadeh C., Perfetti R., Bernier M., and Egan J.M. Regulation of glucose transporters and hexose uptake in 3T3-L1 adipocytes: glucagon-like peptide-1 and insulin interactions. J. Mol. Endocrinol. 19 (1997) 241-248
14. Villanueva-Penacarrillo M.L., Marquez L., Gonzalez N., Diaz-Miguel M., and Valverde I. Effect of GLP-1 on lipid metabolism in human adipocytes. Horm. Metab. Res. 33 (2001) 73-77
15. Alcantara A.I., Morales M., Delgado E., Lopez-Delgado M.I., Clemente F., Luque M.A., et al. Exendin-4 agonist and exendin(9-39)amide antagonist of the GLP-1(7-36)amide effects in liver and muscle. Arch. Biochem. Biophys. 341 (1997) 1-7
16. Luque M.A., Gonzalez N., Marquez L., Acitores A., Redondo A., Morales M., et al. Glucagon-like peptide-1 (GLP-1) and glucose metabolism in human myocytes. J. Endocrinol. 173 (2002) 465-473
17. Acitores A., Gonzalez N., Sancho V., Valverde I., and Villanueva-Penacarrillo M.L. Cell signalling of glucagon-like peptide-1 action in rat skeletal muscle. J. Endocrinol. 180 (2004) 389-398
18. Hansotia T., and Drucker D.J. GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice. Regul. Pept. 128 (2005) 125-134
19. Drucker D.J., and Asa S. Glucagon gene expression in vertebrate brain. J. Biol. Chem. 263 (1988) 13475-13478
20. Orskov C., Poulsen S.S., Moller M., and Holst J.J. Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I. Diabetes 45 (1996) 832-835
21. Tang-christensen M., Vrang N., and Larsen P.J. Glucagon-like peptide (7-36) amide's central inhibition of feeding and peripheral inhibition of drinking are abolished by neonatal monosodium glutamate treatment. Diabetes 47 (1998) 450-537
22. McMahon L.R., and Wellman P.J. PVN infusion of GLP-1-(7-36) amide suppresses feeding but does not induce aversion or alter locomotion in rats. Am. J. Physiol. 274 (1998) 23-29
23. Kinzig K.P., D'Alessio D.A., and Seeley R.J. The diverse roles of specific GLP-1 receptors in the control of food intake and the response to visceral illness. J. Neurosci. 22 (2002) 10470-10476
24. Schirra J., and Goke B. The physiological role of GLP-1 in human: incretin, ileal brake or more?. Regul. Pept. 128 (2005) 109-115
25. Nauck M.A., Niedereichholz U., Ettler R., Holst J.J., Orskov C., Ritzel R., et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am. J. Physiol. 273 (1997) 981-988
26. Wettergren A., Wojdemann M., Meisner S., Stadil F., and Holst J.J. The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation. Gut 40 (1997) 597-601
27. Imeryuz N., Yegen B.C., Bozkurt A., Coskun T., Villanueva Penacarrillo M.L., and Ulusoy N.B. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am. J. Physiol. 273 (1997) 920-927
28. Baggio L.L., Huang Q., Brown T.J., and Drucker D.J. A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes 53 (2004) 2492-2500
29. Schirra J., Wank U., Arnold R., Goke B., and Katschinski M. Effects of glucagon-like peptide-1(7-36)amide on motility and sensation of the proximal stomach in humans. Gut 50 (2002) 341-348
30. Barragan J.M., Eng J., Rodriguez R., and Blazquez E. Neural contribution to the effect of glucagon-like peptide-1-(7-36) amide on arterial blood pressure in rats. Am. J. Physiol. 277 (1999) 784-791
31. Wei Y., and Mojsov S. Tissue-specific expression of the human receptor for glucagon-like peptide 1: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett. 358 (1995) 219-224
32. Yamamoto H., Lee C.E., Marcus J.N., Williams T.D., Overton J.M., Lopez M.E., et al. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J. Clin. Invest. 110 (2002) 43-52
33. Gros R., You X., Baggio L.L., Kabir M.G., Sadi A.M., Mungrue I.N., et al. Cardiac function in mice lacking the glucagon-like peptide-1 receptor. Endocrinology 144 (2003) 2242-2252
34. Nikolaidis L.A., Mankad S., Sokos G.G., Miske G., Shah A., Elahi D., et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 109 (2004) 962-965
35. Barragan J.M., Rodriguez R.E., and Blazquez E. Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7-36) amide in rats. Am. J. Physiol. 266 (1994) 459-466
36. Bose A.K., Mocanu M.M., Carr R.D., Brand C.L., and Yellon D.M. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 54 (2005) 146-151
37. Vila Petroff M.G., Egan J.M., Wang X., and Sollott S.J. Glucagon-like peptide-1 increases cAMP but fails to augment contraction in adult rat cardiac myocytes. Circ. Res. 89 8 (2001) 445-452
38. Hui H., Nourparvar A., Zhao X., and Perfetti R. Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinasedependent pathway. Endocrinology 144 (2003) 1444-1455
39. Tong H., Chen W., Steenbergen C., and Murphy E. Ischemic preconditioning activates phosphatidylinositol-3-kinase upstream of protein kinase C. Circ. Res. 87 (2000) 309-315
40. Mocanu M.M., Bell R.M., and Yellon D.M. PI3 kinase and not p44/42 appears to be implicated in the protection conferred by ischemic preconditioning. J. Mol. Cell. Cardiol. 34 (2002) 661-668
41. Zha J., Harad H., Yang E., Jocke L.J., and Korsmeyer S.J. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 87 (1996) 619-628
42. Richter G., Feddersen O., Wagner U., Barth P., Göke R., and Göke B. GLP-1 stimulates secretion of macromolecules from airways and relaxes pulmonary artery. Am. J. Physiol. Lung Cell. Mol. Physiol. 265 (1993) 374-381
43. Furchgott R.F., and Zawadzki J.V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288 (1980) 373-376
44. Golpon H.A., Puechner A., Welte T., Wichert P.V., and Feddersen C.O. Vasorelaxant effect of glucagon-like peptide-(7-36)amide and amylin on the pulmonary circulation of the rat. Regul. Pept. 102 (2001) 81-86
45. Yu M., Moreno C., Hoagland K.M., Dahly A., Ditter K., Mistry M., et al. Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. J. Hypertens. 21 (2003) 1125-1135
46. Nystrom T., Gutniak M.K., Zhang Q., Zhang F., Holst J.J., Ahren B., et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am. J. Physiol. Endocrinol. Metab. 287 (2004) 1209-1215
47. Perry T., Lahiri D.K., Chen D., Zhou J., Shaw K.T., Egan J.M., et al. A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. J. Pharmacol. Exp. Ther. 300 (2002) 958-966
48. Perry T., Lahiri D.K., Sambamurti K., Chen D., Mattson M.P., Egan J.M., et al. Glucagon-like peptide-1 decreases endogenous amyloid-β peptide (Aβ) levels and protects hippocampal neurons from death induced by Aβ and iron. J. Neurosci. Res. 72 (2003) 603-612
49. During M.J., Cao L., Zuzga D.S., Francis J.S., Fitzsimons H.L., Jiao X., et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat. Med. 9 (2003) 1173-1179
50. Perry T., and Greig N.H. Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer's disease. Curr. Alzheimer Res. 2 (2005) 377-385
51. Perry T.A., and Greig N.H. A new Alzheimer's disease interventive strategy: GLP-1. Curr. Drug Targets 5 (2004) 565-571
52. Perry T., Holloway H.W., Weerasuriya A., Mouton P.R., Duffy K., Mattison J.A., et al. Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy. Exp. Neurol. 203 (2007) 293-301
53. Beak S.A., Heath M.M., Small C.J., Morgan D.G.A., Ghatei M.A., Taylor A.D., et al. Glucagon-like peptide-1 stimulates luteinizing hormone releasing hormone secretion in a rodent hypothalamic neuronal cell line (GT1-7). J. Clin. Invest. 101 (1998) 1334-1341
54. Larsen P.J., Tang-Christensen M., and Jessop D.S. Central administration of glucagon-like peptide-1 activates hypothalamic neuroendocrine neurons in the rat. Endocrinology 138 (1997) 4445-4455
55. Beak S.A., Small C.J., Ilovaiskaia I., Hurley J.D., Ghatei M.A., Bloom S.R., et al. Glucagon-like peptide-1 (GLP-1) releases thyrotropin (TSH): characterization of binding sites for GLP-1 on alpha-TSH cells. Endocrinology 137 (1996) 4130-4138
56. Richter G., Feddersen O., Wagner U., Barth P., Goke R., and Goke B. GLP-1 stimulates secretion of macromolecules from airways and relaxes pulmonary artery. Am. J. Physiol. 265 (1993) 374-381
57. Vara E., Arias-Diaz J., Garcia C., Balibrea J.L., and Blazquez E. Glucagon-like peptide-1(7-36) amide stimulates surfactant secretion in human type II pneumocytes. Am. J. Respir. Crit. Care Med. 163 (2001) 840-846